Overview:

Summary

“Amyotrophic lateral sclerosis (Lou Gehrigs) - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global amyotrophic lateral sclerosis market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global amyotrophic lateral sclerosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global amyotrophic lateral sclerosis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global ALS market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
- Geographies covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases by mechanism of action being developed, and emerging trends. Key classes of mechanism of action include SOD1 protein folding stabilizers, dopamine agonists, immunomodulators and antioxidants.
- Analysis of the current and future market competition in the global ALS market. Key market players covered are Mitsubishi Tanabe Pharma Corporation, Avanir Pharmaceuticals, Avicena Group and Eisai Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with ALS.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global amyotrophic lateral sclerosis market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global amyotrophic lateral sclerosis market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global amyotrophic lateral sclerosis market landscape? – Identify, understand and capitalize.

Companies Mentioned

Mitsubishi Tanabe Pharma Corporation
Eisai Pharmaceuticals
Avanir Pharmaceuticals
Isis Pharmaceuticals
Sangamo BioSciences

1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Amyotrophic Lateral Sclerosis Therapeutics Market: Market Characterization 5
2.1 Overview 5
2.2 ALS Therapeutics Market Size 5
2.3 ALS Therapeutics Market Forecast and CAGR 6
2.4 Drivers and Barriers for the ALS Therapeutics Market 7
2.4.1 Drivers for the ALS Therapeutics Market 7
2.4.2 Barriers for the ALS Therapeutics Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Amyotrophic Lateral Sclerosis Therapeutics Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profile for the Major Marketed Products in the ALS Therapeutics Market 11
3.3.1 Rilutek (Riluzole) 11
3.4 Key Takeaway 12
4 Amyotrophic Lateral Sclerosis Therapeutics Market: Pipeline Assessment 13
4.1 Overview 13
4.2 Strategic Pipeline Assessment 13
4.2.1 Technology Trends Analytic Framework 13
4.3 ALS Therapeutics – Promising Drugs under Clinical Development 14
4.4 Molecule Profile for Promising Drugs under Clinical Development 15
4.4.1 Zenvia 15
4.4.2 Radicut 15
4.4.3 KNS-760704 16
4.4.4 ONO-2506/Cereact 16
4.4.5 SB-509 17
4.4.6 E0302 18
4.4.7 ISIS-SOD1Rx 18
4.5 ALS Therapeutics Market – Clinical Pipeline by Mechanism of Action 19
4.6 ALS Therapeutics Pipeline – Pipeline by Clinical Phases of Development 19
4.6.1 ALS Therapeutics – Phase III Clinical Pipeline 20
4.6.2 ALS Therapeutics – Phase II Clinical Pipeline 20
4.6.3 ALS Therapeutics – Phase I Clinical Pipeline 21
4.6.4 ALS Therapeutics – Pre-clinical Pipeline 22
4.6.5 ALS Therapeutics – Discovery Pipeline 22
4.7 Key Takeaway 23
5 Amyotrophic Lateral Sclerosis Therapeutics Market: Implications for Future Market Competition 24
6 Amyotrophic Lateral Sclerosis Therapeutics Market: Future Players in the ALS Therapeutics Market 25
6.1 Introduction 25
6.2 Mitsubishi Tanabe Pharma Corporation 25
6.2.1 Overview 25
6.2.2 ALS Portfolio 25
6.2.3 ALS Pipeline Portfolio 26
6.3 Eisai Pharmaceuticals 26
6.3.1 Overview 26
6.3.2 ALS Portfolio 26
6.3.3 ALS Pipeline Portfolio 26
6.4 Avanir Pharmaceuticals 27
6.4.1 Overview 27
6.4.2 ALS Portfolio 27
6.4.3 ALS Pipeline Portfolio 27
6.5 Isis Pharmaceuticals 28
6.5.1 Overview 28
6.5.2 ALS Portfolio 28
6.5.3 ALS Pipeline Portfolio 29
6.6 Sangamo BioSciences 29
6.6.1 Overview 29
6.6.2 ALS Portfolio 29
6.6.3 ALS Pipeline Portfolio 30
7 Amyotrophic Lateral Sclerosis Therapeutics Market: Appendix 31
7.1 Definitions 31
7.2 Acronyms 31
7.3 Research Methodology 31
7.3.1 Coverage 32
7.3.2 Secondary Research 32
7.3.3 Forecasting 33
7.3.4 Primary Research 35
7.3.5 Expert Panel Validation 36
7.4 Contact Us 36
7.5 Disclaimer 36
7.6 Sources 36

1.1 List of Tables
Table 1: ALS Therapeutics Market, Global, Revenues, 2001-2009 6
Table 2: ALS Therapeutics Market, Global, Revenue Forecasts, 2009-2016 7
Table 3: Time to ALS Diagnosis 8
Table 4: Major Marketed Products Comparison in the ALS Therapeutics Market, 2010 11
Table 5: ALS Therapeutics – Most Promising Drugs Under Clinical Development, 2010 14
Table 6: ALS Therapeutics – Phase III Clinical Pipeline, 2010 20
Table 7: ALS Therapeutics – Phase II Clinical Pipeline, 2010 20
Table 8: ALS Therapeutics – Phase I Clinical Pipeline, 2010 21
Table 9: ALS Therapeutics – Pre-Clinical Pipeline, 2010 22
Table 10: ALS Therapeutics – Discovery Pipeline, 2010 22
Table 11: Mitsubishi Tanabe Pharma Corporation – ALS Pipeline Products, 2010 25
Table 12: Eisai Pharmaceuticals – ALS Pipeline Products, 2010 26
Table 13: Avanir Pharmaceuticals – ALS Pipeline Products, 2010 27
Table 14: Isis Pharmaceuticals – ALS Pipeline Products, 2010 28
Table 15: Sangamo BioSciences – ALS Pipeline Products, 2010 29

1.2 List of Figures
Figure 1: ALS Therapeutics Market, Global, Revenues, 2001-2009 6
Figure 2: ALS Therapeutics Market, Global, Revenue Forecasts, 2009-2016 7
Figure 3: Opportunity and Unmet Need in the ALS Therapeutics Market, 2010 9
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in ALS Therapeutics, 2010 10
Figure 5: Technology Trends Analytic Framework of the ALS Pipeline, 2010 13
Figure 6: Technology Trends Analytic Framework of the ALS Therapeutics Pipeline – Description, 2010 14
Figure 7: ALS Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 19
Figure 8: ALS Therapeutics Pipeline by Phase of Clinical Development, 2010 19
Figure 9: Implications for Future Market Competition in the ALS Market, 2010 24
Figure 10: ALS Therapeutics Market – Clinical Pipeline by Company, 2010 25
Figure 11: GlobalData Methodology 32
Figure 12: GlobalData Market Forecasting Model 35